Philip McCarthy, MD, Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, provides an overview of the utilization of T-Cell therapies for malignant diseases, with an emphasis on immune effector therapy. This session covers FDA-approved indications for Chimeric Antigen Receptor (CAR) T Cells, as well as the evolving management of CAR T-cell therapy patients, and provides an update on outcome measurements.
Dr. McCarthy also reviews the role of Autologus and Allogeneic blood stem cell transplant in their new environment.
Created by
Related Presenters
Professor of Oncology and Internal Medicine
Director, Transplant & Cellular Therapy Center, Department of Medicine
My research interests are devoted to developing novel intensive and reduced intensity allogeneic and autologous hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes...
BROADCASTMED